New Research Suggests High-Purity CBD May Help Block COVID-19 Virus From Replicating

UChicago researchers found that the COVID-blocking effects of CBD come only from a high-purity, specially formulated dose taken in specific situations. The study’s findings do not suggest that consuming commercially available products with CBD additives that vary in potency and quality can prevent COVID-19.

UChicago Medicine study suggests high-purity CBD may help block virus from replicating.

Researchers recommend clinical trials for CBD to prevent COVID-19 based on promising animal data.

An interdisciplinary team of researchers from the University of Chicago has found evidence that cannabidiol, or CBD, a product of the cannabis plant, can inhibit infection by the COVID-19 virus in human cells and in mice.

The study, published on January 20, 2022, in Science Advances, found CBD showed a significant negative association with positive COVID tests in a national sample of medical records of patients taking the FDA-approved drug for treating epilepsy. The researchers now say that clinical trials should be done to determine whether CBD could eventually be used as a preventative or early treatment for COVID-19.

They caution, however, that the COVID-blocking effects of CBD come only from a high-purity, specially formulated dose taken in specific situations. The study’s findings do not suggest that consuming commercially available products with CBD additives that vary in potency and quality can prevent COVID-19.
An unexpected avenue

The idea to test CBD as a potential COVID-19 therapeutic was serendipitous. “CBD has anti-inflammatory effects, so we thought that maybe it would stop the second phase of COVID infection involving the immune system, the so-called ‘cytokine storm,’” said Marsha Rosner, Charles B. Huggins Professor in the Ben May Department of Cancer Research and a senior author of the study. “Surprisingly, it directly inhibited viral replication in lung cells.”

To see this effect, the researchers first treated human lung cells with a non-toxic dose of CBD for two hours before exposing the cells to the COVID virus and monitoring them for the virus and the viral spike protein. They found that, above a certain threshold concentration, CBD inhibited the virus’ ability to replicate. Further investigation found that CBD had the same effect in two other types of cells and for three variants of the COVID virus in addition to the original strain.

CBD did not affect the ability of the virus to enter the cell. Instead, CBD was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell.

“No one in their right mind would have ever thought that it blocked viral replication, but that’s what it did.”

Prof. Marsha Rosner

Like all viruses, the COVID virus affects the host cell by hijacking its gene expression machinery to produce more copies of itself and its viral proteins. This effect can be observed by tracking virus-induced changes in cellular RNAs. High concentrations of CBD almost completely eradicated the expression of viral RNAs. It was a completely unexpected result.

“We just wanted to know if CBD would affect the immune system,” Rosner said. “No one in their right mind would have ever thought that it blocked viral replication, but that’s what it did.”

The researchers showed that the mechanism by which CBD blocks the COVID virus replication involves CBD activation of one of the host cell stress responses and generation of interferons, an antiviral cell protein.

Real-world data: Patients taking CBD test positive for COVID-19 at lower rates

The researchers wanted scientific data to show that CBD prevents viral replication in live animals. The team showed pretreatment with CBD for one week prior to infection with the virus suppressed infection both in the lung and the nasal passages of mice. “These results provide major support for a clinical trial of CBD in humans,” said Rosner.

And the success of CBD wasn’t limited to the laboratory: An analysis of 1,212 patients from the National COVID Cohort Collaborative revealed that patients taking a medically prescribed oral solution of CBD for the treatment of epilepsy tested positive for COVID-19 at significantly lower rates than a sample of matched patients from similar demographic backgrounds who were not taking CBD.

The potential for CBD to treat patients recently exposed to or infected by SARS-CoV-2—the virus that causes COVID—does not precede the first lines of defense against COVID-19, which are to get vaccinated and follow existing public health guidelines for masking in indoor spaces and social distancing. But the published results offer a potential new therapeutic, something still needed as the pandemic rages on.

“A clinical trial is necessary to determine whether CBD is really effective at preventing or suppressing SARS-CoV-2 infection, but we think this may have potential as a prophylactic treatment,” said Rosner. “Maybe you’re in a hot spot or you think you might have been exposed or you’ve just tested positive—that’s where we think CBD might have an effect.”

Not your dispensary’s CBD

The research team emphasized that the COVID-blocking effects of CBD were confined strictly to high purity, high concentrations of CBD. Closely related cannabinoids such as CBDA, CBDV and THC, the psychoactive element enriched in marijuana plants, did not have the same power. In fact, combining CBD with equal amounts of THC actually reduced the efficacy of CBD.

“Going to your corner bakery and buying some CBD muffins or gummy bears probably won’t do anything,” said Rosner. “The commercially available CBD powder we looked at, which was off the shelf and something you could order online, was sometimes surprisingly of high purity but also of inconsistent quality. It is also hard to get into an oral solution that can be absorbed without the special, FDA-approved formulation.”

“Going to your corner bakery and buying some CBD muffins or gummy bears probably won’t do anything.”

Prof. Marsha Rosner

Furthermore, CBD use is not without potential risks. It appears to be extremely safe when consumed in food or drink, but methods of use such as vaping can have negative side effects, including potential damage to the heart and lungs. It’s also not well studied in certain populations, such as pregnant people, and so should be used only under the supervision of a physician and with caution.

While the study’s results are exciting, additional study is needed to determine the precise dosing of CBD that is effective at preventing infection in humans as well as its safety profile and any potential side effects.

“We are very eager to see some clinical trials on this subject get off the ground,” Rosner said. “Especially as we are seeing that the pandemic is still nowhere near the end—determining whether this generally safe, well-tolerated and non-psychoactive cannabinoid might have anti-viral effects against COVID-19 is of critical importance.”

Rosner was also pleased that this research project was a case study in the power of scientific collaboration by bringing together a highly interdisciplinary group of researchers. Senior authors listed on the paper came from three different research universities and from departments as diverse as microbiology, molecular engineering, cancer biology and chemistry.

“This was truly a team-science effort, and that’s something that really excites me,” said Rosner. “From clinicians to David Meltzer’s group who did the patient analysis to virologists like Glenn Randall, and it goes on and on. This is the way science should be carried out.”

Additional authors include Long Chi Nguyen, Dongbo Yang, Thomas J. Best, Nir Drayman, Adil Mohamed, Christopher Dann, Diane Silva, Lydia Robinson-Mailman, Andrea Valdespino, Letícia Stock, Eva Suárez, Krysten A. Jones, Saara-Anne Azizi, James Michael Millis, Bryan C. Dickinson, Savaş Tay, Scott A. Oakes, and David O. Meltzer of the University of Chicago; Vlad Nicolaescu, Haley Gula, and Glenn Randall of UChicago and Argonne National Laboratory; Divayasha Saxena, Jon D. Gabbard, Jennifer K. Demarco, William E. Severson, Charles D. Anderson, and Kenneth E. Palmer of the University of Louisville; Shao-Nong Chen, Takashi Ohtsuki, John Brent Friesen, and Guido F. Pauli of the University of Illinois at Chicago; and the National COVID Cohort Collaborative Consortium.

Reference: “Cannabidiol Inhibits SARS-CoV-2 Replication through Induction of the Host ER Stress and Innate Immune Responses” by Long Chi Nguyen, Dongbo Yang, Vlad Nicolaescu, Thomas J. Best, Haley Gula, Divyasha Saxena, Jon D. Gabbard, Shao-Nong Chen, Takashi Ohtsuki, John Brent Friesen, Nir Drayman, Adil Mohamed, Christopher Dann, Diane Silva, Lydia Robinson-Mailman, Andrea Valdespino, Letícia Stock, Eva Suárez, Krysten A. Jones, Saara-Anne Azizi, Jennifer K. Demarco, William E. Severson, Charles D. Anderson, James Michael Millis, Bryan C. Dickinson, Savas Tay, Scott A. Oakes, Guido F. Pauli, Kenneth E. Palmer, The National COVID Cohort Collaborative Consortium, David O. Meltzer, Glenn Randall and Marsha Rich Rosner, 20 January 2022, Science Advances.
DOI: 10.1126/sciadv.abi6110

Funding: BIG Vision grant from the University of Chicago, the National Institutes of Health, Harry B. and Leona M Helmsley Charitable Trust.

CannabisCBDCOVID-19Infectious DiseasesPopularPublic HealthUniversity of ChicagoVirology
Comments ( 5 )
Add Comment
  • wbrab

    * Research non-peer reviewed and paid for by CBDRocksDudes.com

  • Clyde Spencer

    “… the COVID-blocking effects of CBD come only from a high-purity, specially formulated dose taken in specific situations.”

    One has to be jumping up and down on one leg, while rubbing their abdomen and patting their head, and reciting Hamlet’s soliloquy backwards.

    Seriously, there have been so many things reported to ‘possibly’ be effective against SARS-COV-2 that this isn’t really surprising. There is reason to believe that at least some of the responses can be attributed to a placebo effect.

  • Gao-De Li

    The reason why a virus can infect its target cells is because the target cell’s gene expression pattern is suitable for the viral infection. Gene expression pattern in a cell type is determined by 3D genome architecture and genotoxic agents (including chemical, physical and biological agents) are only agents that can be used to alter 3D genome architecture. We think that some old drugs with genotoxic side effects could be used to temporarily alter 3D genome architecture in the viral target cells so that the gene expression pattern in the viral target cells could be temporarily altered, which might reduce the target cell’s susceptibility to viral infection, enabling the viral target cells to temporarily become ‘non-viral target cells’. This strategy could be used to prevent all viral infections including infections with variant viruses. Currently, all reported drugs that show preventive and curative effects on COVID-19 have genotoxic side effects, which strongly supports our antiviral-pandemic theory. CBD is an agent with genotoxic side effects and therefore could be used for preventing COVID-19.

  • drob

    the COVID-blocking effects of CBD come only from a high-purity, specially formulated dose taken in specific situations.”

    but then say there test group has been patients taking CBD for epilepsy… which the dose is 5-50mg per day… this is a very normal dose for anyone taking CBD and it is something that you can easily find if you have real cannabis derived CBD. Half of this article talks about how this is not your average CBD dose however it is and that’s why you were able to study this group.

  • Clyde Spencer

    You have attempted to avoid automated spam filters by not-so-clever capitalization. That demonstrates that you know that what you are doing is against rules. You checked the box confirming you are NOT a spammer. That is, you lied. Why should anyone believe your claims when you have demonstrated that you have no problem lying? Get a real job!